Driven by the availability of Merck KGaA’s Mavenclad and substantial uptake of Biogen’s Tecfidera, the oral disease-modifying therapy (DMT) class share of DMT-treated multiple sclerosis (MS) patients increased significantly in the EU over the past six months, putting significant pressure on Teva’s Copaxone.
A survey of 104 US rheumatologists in August revealed significantly fewer patients with nr-axSpA are treated with biologic/JAK agents compared to patients with AS, despite the majority of these patients being considered biologic-eligible.
Unaided awareness of Novartis’ siponimod increased compared to previous quarters, but neurologists appear split on how, or if, they will incorporate siponimod into their multiple sclerosis armamentarium.
Janssen’s Tremfya continues to post gains, but may soon face competition as Sun Dermatology readies for the launch of Ilumya (tildrakizumab), the second IL-23 inhibitor to be introduced in the US market, according to a new report from Spherix Global Insights
Spherix recently published RealWorld Dynamix™: Systemic Lupus Erythematosus US, which analyzed 1,032 patient charts from 201 rheumatologists. The below spotlight is an example of one patient profile from this robust audit.